Omission of Intact Parathyroid Hormone Testing During Surgery in Treating Patients With Primary Hyperparathyroidism
Status: | Active, not recruiting |
---|---|
Conditions: | Endocrine |
Therapuetic Areas: | Endocrinology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 2/3/2019 |
Start Date: | May 12, 2016 |
End Date: | December 28, 2019 |
Single-Arm, Non-inferiority Study of Omission of Intraoperative Intact Parathyroid Hormone (PTH) During Minimally Invasive Parathyroidectomy for Primary Hyperparathyroidism
This clinical trial studies the omission of intact parathyroid hormone testing during surgery
in treating patients with primary hyperparathyroidism. Omission of intact parathyroid hormone
testing during parathyroid gland removal may help patients with primary hyperparathyroidism
to decrease their time under anesthesia, and decrease the overall time and cost of surgery.
in treating patients with primary hyperparathyroidism. Omission of intact parathyroid hormone
testing during parathyroid gland removal may help patients with primary hyperparathyroidism
to decrease their time under anesthesia, and decrease the overall time and cost of surgery.
PRIMARY OBJECTIVES:
I. Determine the non-inferiority of omission of parathyroid hormone (PTH) in patients who
meet the biochemical and radiological criteria compared to current standard of care (i.e. use
of intraoperative parathyroid hormone testing).
SECONDARY OBJECTIVES:
I. Cost-analysis to determine savings of omission of intraoperative PTH testing.
OUTLINE:
Patients undergo standard minimally invasive parathyroidectomy without PTH testing during
surgery.
After completion of study, patients are followed up at 2 weeks.
I. Determine the non-inferiority of omission of parathyroid hormone (PTH) in patients who
meet the biochemical and radiological criteria compared to current standard of care (i.e. use
of intraoperative parathyroid hormone testing).
SECONDARY OBJECTIVES:
I. Cost-analysis to determine savings of omission of intraoperative PTH testing.
OUTLINE:
Patients undergo standard minimally invasive parathyroidectomy without PTH testing during
surgery.
After completion of study, patients are followed up at 2 weeks.
Inclusion Criteria:
- Positive 4 dimensional computed tomography (4D CT) for single gland (adenoma) primary
hyperparathyroidism
- Preoperative serum calcium levels >= 10.9 mg/dL
- Preoperative parathyroid hormone (PTH) elevated beyond normal range or inappropriately
high for associated calcium level
- Patient has no history of prior neck surgery or external radiation to neck for
malignant conditions
- Have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 2
- Subject or legal representative must understand the investigational nature of this
study and sign an Independent Ethics Committee/Institutional Review Board approved
written informed consent form prior to receiving any study related procedure
Exclusion Criteria:
- Patient has recurrent hyperparathyroidism
- 4D CT positive for multiple gland disease
- Patient has inability to tolerate 4D CT scan (for example; contrast intravenous (IV)
allergy, claustrophobia, renal disease)
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active
infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
arrhythmia, or psychiatric illness/social situations that would limit compliance with
study requirements
- Pregnant or nursing female subjects; may be determined in the preoperative evaluation
- Unwilling or unable to follow protocol requirements
- Any condition which in the investigator's opinion deems the subject an unsuitable
candidate to undergo observational study (may also include preoperative testing
results including electrocardiography [EKG], chest x-ray, or pulmonary function tests
that preclude a wide excision in the operating room)
We found this trial at
1
site
666 Elm Street
Buffalo, New York 14263
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Moshim Kukar
Phone: 877-275-7724
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials